Navigation Links
InspireMD to Ring Opening Bell at New York Stock Exchange on Thursday, October 24th
Date:10/23/2013

BOSTON, Oct. 23, 2013 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will ring the Opening Bell at the New York Stock Exchange on Thursday, October 24, 2013 at 9:30 a.m. ET.

Representing the Company, Alan Milinazzo, Chief Executive Officer, and Craig Shore, Chief Financial Officer, will be joined by members of the InspireMD management team to ring the Opening Bell.

"We look forward to ringing the Opening Bell at the New York Stock Exchange as we celebrate the progress made by the Company over the past year," said Alan Milinazzo, Chief Executive Officer of InspireMD.  "Over the next year, we are looking forward to several exciting milestones within our clinical and product development programs, as well as for our commercialization operations.  This includes the announcement next week of 12-month follow-up data for the MASTER trial in San Francisco at the Transcatheter Cardiovascular Therapeutics (TCT) Conference on October 29th."

A live webcast of the NYSE Opening Bell Ceremony will be available online at:
https://nyse.nyx.com/the-bell/todays-bells-live.

A replay of the NYSE Opening Bell Ceremony and photos from the event will be available at:
www.Inspire-MD.com or https://exchanges.nyx.com/new-york-stock-exchange-0.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MGuard™ technology to make its products the industry standard for embolic protection stents and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures.  InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

MGuard™ EPS is CE Mark approved. It is not approved for sale in the U.S. by the FDA at this time.

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
Phone: 212-896-1215 / 212-896-1250
Email: tfromer@kcsa.com / grussell@kcsa.com

Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
Phone: 212-896-1216 / 212-896-1220
Email: lgoldberg@kcsa.com / swolf@kcsa.com


'/>"/>
SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
2. InspireMD Appoints David Blossom as Vice President of Global Marketing and Strategy
3. InspireMD Announces Participation in Two Investor Conferences in September
4. InspireMD Completes First Phase of Manufacturing Upgrade and Partners with HealthLink for Global Logistics and Distribution Services
5. InspireMDs MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group
6. InspireMD Reports Financial Results For Period Ended March 31, 2013
7. InspireMD Receives Approval From US Food and Drug Administration to Begin US Regulatory Trial
8. InspireMD Closes $25 Million Underwritten Public Offering
9. InspireMD Announces Pricing of Underwritten Public Offering of Common Stock and Listing on NYSE MKT
10. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
11. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... NEW YORK , Jan. 19, 2017 /PRNewswire/ ... reach USD 233.7 billion by 2025, according to ... The market is anticipated to be predominantly driven ... companies, resulting into the large-scale production of new ... widen the influx of drugs at an unprecedented ...
(Date:1/19/2017)... -- Report Details ... Alzheimer,s Disease Therapeutics and Diagnostics ... new study reveals trends, R&D progress, and predicted revenues ... Alzheimer,s disease therapeutics and diagnostics market. Our new report ... How is the Alzheimer,s disease therapeutics and diagnostics market ...
(Date:1/19/2017)... According to a study conducted by Persistence Market Research ... CAGR of 6.5% during the forecast period 2016-2024. According to the ... the leading market for cryotherapy globally during the forecast period  ... Highlights from the Report  ... adequate supply of gas in order to provide smoother maintenance services ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... ... has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound ... extension to RMT technology that delivers HD, dynamic, streaming ultrasound images and video ...
(Date:1/19/2017)... ... 19, 2017 , ... Dr. Andrew Lian-Jie Li ... trained Mohs and cosmetic surgeon. After extensive dermatology research training at the National ... in internal medicine at the Emory University and dermatology training at the University ...
(Date:1/19/2017)... Texas (PRWEB) , ... January 19, 2017 , ... Students ... GenCure Tissue Donation Awareness Scholarship competition., The winner will earn a $1,000 scholarship and ... The competition begins Feb. 1, and the deadline is May 31, with the winner ...
(Date:1/19/2017)... ... January 19, 2017 , ... Allegheny Health Network (AHN) officials today ... access to the Network’s programs and services in the greater Pittsburgh region. Starting January ... will be offered one for that same afternoon. , AHN is ...
(Date:1/19/2017)... ... 2017 , ... For the third year running, Noto Insurance ... surrounding area, is inaugurating a charity event to help raise funds for ... Gehrig's disease or motor neurone disease, is a deadly neurological disorder that affects ...
Breaking Medicine News(10 mins):